CHENGDU, China, March 11 Viscorp Inc.(OTC Bulletin Board: VSCO; TYNP), a manufacturer and supplier of modernizedtraditional Chinese medicine ("TCM") based in Chengdu, China, today announcedthat it has changed its name to Tianyin Pharmaceutical, Co., Inc. Thecorporate name change is effective immediately.
In addition, effective March 11, 2008, the Company will trade under a newsymbol TYNP with the new CUSIP Number of 88630M 104.
Viscorp and Raygere Ltd, which conducts its business through ChengduTianyin Pharmaceutical Co., LTD. ("Tianyin"), jointly announced on January 16,2008, that the companies completed a Definitive Share Exchange Agreementwhereby Viscorp acquired all of the outstanding and issued shares of Tianyin.
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. It has a comprehensive productportfolio of 34 modernized TCMs in the market, 22 of which are listed in thehighly selective National Medicine Catalog of the National Medical InsuranceProgram. Tianyin owns and operates two GMP manufacturing facilities and anR&D platform supported by leading Chinese academic institutions. The Companyhas a pipeline of 51 pharmaceutical products pending approval. Tianyin has anextensive nationwide distribution network throughout China with a sales forceof 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Provincewith two manufacturing facilities and a total of 869 employees. Tianyinachieved revenue of $20.4 million and net income of $3.95 million in FY2007ending June 30, 2007.
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO Tel: +86-158-2122-5642 Email: Allen.firstname.lastname@example.org Investors: HC International Alan Sheinwald Tel: +1-914-669-0222 Email: Alan.Sheinwald@hcinternational.net
SOURCE Tianyin Pharmaceutical, Co., Inc.